Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05579171
Other study ID # Potenza-Picosure-Acne Scars
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 1, 2022
Est. completion date October 30, 2023

Study information

Verified date October 2022
Source Goldman, Butterwick, Fitzpatrick and Groff
Contact Andrea Pacheco
Phone 8586571004
Email apacheco@clderm.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess efficacy and safety of paired picosecond 755nm Alexandrite laser with focused lens array (PSAL; Picosure®, Cynosure, Westford, MA) and radiofrequency microneedling (RFM; Potenza™, Cynosure, Westford, MA) for treatment of facial, atrophic acne scars.


Description:

The primary objective of this clinical trial is to assess efficacy and safety of combination treatment with fractional picosecond 755nm Alexandrite laser with focused lens array (Picosure®, Cynosure, Westford, MA) and radiofrequency microneedling (Potenza™, Cynosure, Westford, MA) for treatment of facial, atrophic acne scarring. Enrolled subjects will be randomized to receive picosecond 755 nm Alexandrite laser treatment to either the left or right facial half. The subjects will then undergo full face radiofrequency microneedling (RFM). Subjects satisfying all inclusion and no exclusion criteria will be enrolled in this trial. Prior to receiving any study treatment, mandatory digital photographs will be obtained of each subject's treatment area. In order to participate in the study, subjects must provide written informed consent to have their photographs used for research, publication, and/or commercial purposes.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date October 30, 2023
Est. primary completion date October 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult males and females aged 18 or older - Subjects in good general health based on investigator's judgment and medical history - Moderate to severe atrophic acne scarring on the face per ECCA (échelle d'évaluation clinique des cicatrices d'acné) acne grading scale - Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study - Understands and accepts the obligation and is logistically able to be present for all visits - Is willing to comply with all requirements of the study and sign the informed consent documents - Must be willing to maintain usual sun exposure for the duration of the study - Subject agrees to avoid tanning or use of sunless tanner during the entire course of the study - Negative urine pregnancy test result at the time of study entry (if applicable) - For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment. 1. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation. 2. Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g., condoms and spermicide), abstinence, and/or vasectomy of partner with a documented second acceptable method of birth control, should the subject become sexually active. Exclusion Criteria: - Female subjects who are pregnant, planning a pregnancy, or breast feeding during the study - The subject is hypersensitive to light in the near infrared wavelength region - The subject is taking medication which is known to increase sensitivity to sunlight - The subject has a seizure disorders triggered by light - The subject is receiving or have received gold therapy - The subject has a pacemaker - The subject has a metal implant that interferes with the transmission of energy to the electrical field - The subject has any embedded electronic devices that give or receive a signal such as Implantable Cardiac Defibrillators (ICD) or Cardiac Resynchronization Therapy (CRT) devices: treatment may interfere with the functionality of the device and/or damage the electronic implant - Gold allergy - The subject has nerve insensitivity to heat in the treatment area or in the neutral pad placement area or a neuropathic disorder - The subject has severe laxity or sagging that causes redundant folds of tissue or hanging skin in the area to be treated - Dermal fillers, neuromodulator, biostimulatory injectables, fat grafting, radiofrequency device treatments, microfocused ultrasound device treatments, laser and light-based device treatments, microneedling to the face during the 6-month period before study treatment m) Subjects with tattoos in the treatment areas n) Subjects with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study - Subjects with a history of or presence of any skin condition/disease (including but not limited to any visible rash, atopic dermatitis, psoriasis, actinic keratoses, keratinocyte carcinoma, melanoma, etc.) in the treatment area that might interfere with the diagnosis or evaluation of study parameters - History of keloid or hypertrophic scarring - Subjects with an active bacterial, viral, or fungal infection of the treatment areas - The subject has a significant systemic illness, such as lupus, or an illness localized in area being treated - History of lidocaine sensitivity deemed by the investigator to preclude the subject from enrolling into the study - Subjects planning any cosmetic procedure to the treatment areas during the study period, other than the treatment that will be performed by the investigator - Presence of incompletely healed wound(s) in the treatment area - Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Picosecond 755nm Alexandrite Laser
Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
Picosecond 755nm Alexandrite Laser
Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Goldman, Butterwick, Fitzpatrick and Groff Cynosure, LLC

Outcome

Type Measure Description Time frame Safety issue
Primary Volumetric analysis of change in treatment zone for acne scars using 3D imaging 3D photography will be taken
Standardized 3D Vectra Photography with standard lighting and camera positioning to ensure comparable before and after treatment photographs of the face. Photographs will be taken, capturing three (3) views of the hip area: anterior, right oblique (45°), and left oblique (45°). 3D photography is taken at every time frame to compare the appearance of acne scars to the previous photo.
Baseline, Day 7, Day 35, Day 63, Day 91, Day 121, Day 181, Day 271
Primary ECCA acne grading scale by blinded investigator to assess change Blinded Investigator ECCA (e´chelle d'e´valuation clinique des cicatrices d'acne´) acne grading scale
V-Shaped atrophic scars, diameter of less than 2mm, and punctiform 0= no scar
a few scars
limited number of scars
many scars
U-shaped atropic scars, diameter of 2-4 mm, with sheer edges 0= no scar
a few scars
limited number of scars
many scars
M-shaped atrophic scars, diameter of more than 4mm, superficial and with irregular surface 0= no scar
a few scars
limited number of scars
many scars
Superficial elastolysis 0= absent
mild
moderate
intense
Hypertrophic inflammatory scars, scars of less than 2 years of age 0= no scar
a few scars
limited number of scars
many scars
Keloid scars, hypertrophic scars, of more than 2 years of age 0= no scar
a few scars
limited number of scars
many scars
Day 7, Day 35, Day 63, Day 91, Day 121, Day 181, Day 271
Primary Physician Global Aesthetic Improvement Scale (PGAIS) by blinded investigator Blinded Investigator Global Aesthetic Improvement Scale Assessment (PGAIS)
Rating Description
Very Much Improved: Optimal cosmetic result in this subject.
Much Improved: Marked improvement in appearance from the initial condition, but not completely optimal for this subject.
Improved: Obvious improvement in appearance from initial condition, but a re-treatment is indicated.
No Change: The appearance is essentially the same as the original condition.
Worse: The appearance is worse than the original condition.
Scores (write a number under each treated area or check "Not Treated") Left Facial Half Right Facial Half
Not Treated Not Treated
Day 35, Day 63, Day 91, Day 121, Day 181, Day 271
Primary Blinded Identification of correct treatment area by blinded investigator The baseline (Day 0) and 6 month (Day 259) photographs will be randomly put side-by-side and labeled either (A) or (B). The blinded investigator will then fill out the following:
Do you see an improvement in photoaging between the two sets of photos? (Yes / No)
If yes to question #1:
Which is the post-treatment photograph? (A / B)
Which is the treatment side? (Right / Left)
Day 271
Secondary Subject Global Aesthetic Improvement Scale (SGAIS) Subject Global Aesthetic Improvement Scale Assessment (SGAIS)
How would you rate the change in appearance of your treated areas? Non-treated areas will be checked as "Not Treated" for you.
Rating Description
Very Much Improved: Optimal cosmetic result
Much Improved: Marked improvement in appearance form the initial condition, but not completely optimal
Improved: Obvious improvement in appearance from initial condition
No Change: The appearance is essentially the same as the original condition
Worse: The appearance is worse than the original condition Scores (write a number to rate each treated area) Left Facial Half Right Facial Half
Not Treated Not Treated
Day 35, Day 63, Day 91, Day 121, Day 181, Day 271
Secondary Evaluation of side effects by investigators Treating Investigator Evaluation of Side Effects Rating Description 0 NONE: Normal
TRACE: Barely visible and localized
MILD: Somewhat visible and diffuse
MODERATE: Visible and diffuse
SEVERE: Extremely visible and dense SCORES (write number under each treated area or check "Not Treated")
Erythema Left Facial Half Right Facial Half
Not Treated Not Treated
Edema Left Facial Half Left Facial Half
Not Treated Not Treated
Bruising/Petechiae Left Facial Half Left Facial Half
Not Treated Not Treated
Ulcers Left Facial Half Left Facial Half
Not Treated Not Treated
Hyperpigmentation/Hypopigmentation Left Facial Half Left Facial Half
Not Treated Not Treated
Day 7, Day 35, Day 63, Day 91, Day 121, Day 181, Day 271
Secondary Ultrasound imaging measurements of dermal edema Treating investigator measurement of Sub-Dermal Edema by ultrasonography
Treating Investigator Measurement of Sub-Dermal Edema by Ultrasonography Depth of dermis (mm) Ultrasound images will be obtained at the point of intersection when a horizontal line is drawn from the ala to the tragus and a vertical line is drawn from the lateral canthus to the lateral oral commissure.
Left Facial Half Right Facial Half
Day 7, Day 35, Day 63, Day 91
See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Active, not recruiting NCT01696513 - Effect of Subcision and Suction on Acne Scars N/A
Completed NCT01115634 - Autologous Fibroblast Transplantation in Facial Deformities Phase 2
Completed NCT05254210 - Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device N/A
Completed NCT05102617 - Post Market Usability Evaluation Of The PicoSure Pro Device N/A
Completed NCT02103816 - The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars N/A
Completed NCT01221922 - Laser Treatment of Acne Scars in Fitzpatrick Skin Types III-VI N/A
Completed NCT03767153 - Clinical Evaluation of Fractional Radiofrequency for the Treatment of Acne Scarring N/A
Completed NCT00974870 - A Pilot Study Testing the Efficacy of a Needling Device for the Treatment of Acne Scars N/A
Completed NCT02145364 - Ultherapy® for the Treatment of Acne Scars N/A
Not yet recruiting NCT02126657 - The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne Scars Phase 2
Enrolling by invitation NCT01847066 - Epidermal Delivery of Ani-Aging Ingredients N/A
Recruiting NCT03850925 - Comparison of Picosecond Pulsed Nd:YAG Laser and Fractional Laser for the Treatment of Acne Scars N/A
Active, not recruiting NCT04807179 - Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne Scars N/A
Terminated NCT02955381 - Restylane Silk Acne Scar Efficacy Evaluation Study N/A
Completed NCT01213199 - Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars Phase 2
Completed NCT03380845 - Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin N/A
Active, not recruiting NCT03901417 - Comparison of 1550nm Fractional Laser Alone Versus in Combination With Microneedling for the Treatment of Acne Scars N/A
Completed NCT03522922 - Efficacy of Microneedling With Topical Vitamin C in Treatment of Acne Scarring Phase 1/Phase 2
Recruiting NCT05987319 - Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions N/A